Do SSRIs differ in their antidepressant efficacy

Human Psychopharmacology: Clinical and Experimental

Volumn 10, Issue 3 S, 1995, Pages S163-S172

  Kasper, S ^a   Heiden, A ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

depression; efficacy; selective serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIMELDINE;

DEPRESSION; DRUG EFFICACY; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SUICIDAL BEHAVIOR;

EID: 0029163299     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.470100905     Document Type: Article

References (89)

1. Double‐blind study of the efficacy and safety of sertraline versus fluoxetine in major depression
2. Fluoxetine compared with amitriptyline in elderly depression, a controlled clinical trial
3. Fluvoxamine: antidepressant effects confirmed in a placebo‐controlled international study
4. The efficacy of selective serotonin re‐uptake inhibitors in depression: a meta‐analysis of studies against tricyclic antidepressants
5. A double‐blind comparison of paroxetine and fluvoxamine in major depression
6. Fluoxetine and side effects
7. 5‐HT reuptake inhibitors, tricyclic antidepressants and suicidal behaviour
8. Fluoxetine and suicide: a meta‐analysis of controlled trials of treatment for depression
9. Fluoxetine compared with imipramine in the treatment of inpatient depression
10. The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders—a double blind placebo‐controlled study
11. Adverse effects of antidepressant drugs. Part 1. Monoamine oxidase inhibitors and tricyclics
12. The pharmacogenetics of the selective serotonin reuptake inhibitors
13. Are patients who are intolerant to one SSRI intolerant to another?
14. Paroxetine and extrapyramidal reactions (letter)
15. A double‐blind comparison of paroxetine with imipramine in the long‐term treatment of depression
16. Double‐blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients
17. The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects
18. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study
19. Paroxetine: A SSRI showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study
20. A randomized, double‐blind study of fluoxetine and maprotiline in the treatment of major depression
21. A double‐blind, comparative, multicentre study comparing paroxetine and fluoxetine in depressed patients
22. Sertraline in the prevention of depression
23. Sleep and paroxetine: a comparison with mianserin in elderly depressed patients
24. Paroxetine in the treatment of severe (melancholic). depression
25. Two combined, multicenter double‐blind studies of paroxetine and doxepin in geriatric patients with major depression
26. Depression in elderly physically ill in‐patients: a 12‐month prospective study
27. Suicidality and fluoxetine: is there a relationship?
28. A placebo‐controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression
29. An overview of fluoxetine in geriatric depression
30. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions
31. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects
32. Treatment of depression in elderly patients with and without dementia disorders
33. Paroxetine, sertraline and fluvoxamine: new selective serotonin reuptake inhibitors
34. Fluvoxamine and imipramine: results of a long‐term controlled trial
35. A double‐blind multicentre study of paroxetine versus clomipramine in depressed elderly patients
36. Sertraline: a new specific serotonin reuptake blocker
37. Toxicity of antidepressants
38. Suicide and fatal antidepressant poisoning
39. Effect of fluvoxamine on panic disorder
40. A double blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients
41. Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs)
42. Pharmacological characterisation of selective serotonin reuptake inhibitors (SSRIs)
43. The comparative pharmacological properties of selective serotonin reuptake inhibitors in animals
44. Is severe depression a different illness? The pharmacological evidence
45. The rationale for long‐term antidepressant therapy
46. Comparative efficacy of antidepressants
47. Safety and antidepressant efficacy of selective serotonin re‐uptake inhibitors
48. Efficacy, safety and indications for tricyclic and the newer antidepressants
49. Antidepressant efficacy in relation to item analysis and severity of depression: a placebo‐controlled trial of fluvoxamine versus imipramine
50. A multicentre double‐blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice
51. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance
52. The comparative pharmacology of new antidepressants
53. Fluoxetine induced akathisia: clinical and therapeutic implications
54. Paroxetine: pharmacokinetic and antidepressant effect in the elderly
55. Efficacy of new generation antidepressants: Meta‐analysis of imipramine controlled studies
56. Are serotonergic reuptake inhibitors more potent in reducing suicidality? An empirical study on paroxetine
57. The efficacy of fluoxetine as an antidepressant in the short and long term
58. The prophylactic efficacy of fluoxetine in unipolar depression
59. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta‐analysis
60. Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression
61. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
62. The efficacy of fluvoxamine in patients with severe depression
63. Fluoxetine—a clinical and research update. Severity of depression and response to fluoxetine
64. A double‐blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people
65. Safety and tolerance of fluvoxamine in cardiac patients
66. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline
67. A double‐blind randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients
68. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia
69. Re‐exposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia
70. Traitment par la fluvoxamine (Floxyfral). d'episodes depressifs majeurs chez des patients de plus de 65 ans
71. A double‐blind study of paroxetine compared with fluoxetine in geriatric patients with major depression
72. Fluoxetine: a serotonin‐specific second generation antidepressant
73. Fluoxetine: a five‐year review
74. Emergence of intense suicidal preoccupation during fluoxetine treatment
75. A double‐blind randomized, fluoxetine‐controlled multicentre study of paroxetine in the treatment of depression
76. A double‐blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients
77. Analysis of the Hamilton Depression Rating Scale factors from a double‐blind, placebo controlled trial of fluoxetine in geriatric major depression
78. Adverse reactions to drugs used in the treatment and prophylaxis of depression and mania
79. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
80. Safety database on fluvoxamine: analysis and report
81. Fluvoxamine in the treatment of the older depressed patient; double‐blind, placebo‐controlled data
82. A double‐blind placebo‐controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers